• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Ainos Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Leadership Update, Financial Statements and Exhibits

    8/9/24 4:05:33 PM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AIMD alert in real time by email
    false 0001014763 0001014763 2024-08-05 2024-08-05 0001014763 AIMD:CommonStockParValue0.01PerShareMember 2024-08-05 2024-08-05 0001014763 AIMD:WarrantsToPurchaseCommonStockMember 2024-08-05 2024-08-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): August 5, 2024

     

    AINOS, INC.
    (Exact name of registrant as specified in its charter)

     

    Texas   001-41461   75-1974352

    (State or other Jurisdiction

    of Incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    8880 Rio San Diego Drive, Ste. 800, San Diego, CA 92108

    (858) 869-2986

    (Address and telephone number, including area code, of registrant’s principal executive offices)

     

    (Former name or former address if changed since last report.)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.01 per share   AIMD   The Nasdaq Stock Market LLC
    Warrants to purchase Common Stock   AIMDW   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     
     

     

    Item 1.01 Entry into a Material Definitive Agreement.

     

    Patent License Agreement

     

    On August 6, 2024, Ainos, Inc., a Texas corporation (the “Company”) entered into a patent license agreement (the “License Agreement”) with Taiwan Carbon Nano Technology Corporation (“TCNT”), as an effort to bolster the Company’s AI Nose and point-of-care testing (POCT) technologies while preserving cash. As of August 5, 2024, prior to TCNT entering into the License Agreement, TCNT controlled, via its majority interest in Ainos Inc., a Cayman Islands corporation (“Ainos KY”) which is a party to certain previously disclosed Voting Agreements, approximately 38% of the voting power of the Company. Pursuant to the License Agreement, TCNT has agreed to assign and grant, and the Company has agreed to accept, an exclusive, irrevocable, and perpetual license of certain invention patents and patent applications related to gas sensors and medical devices (the “Licensed Patents”), in exchange for 5,500,000 shares of the Company’s common stock (the “Common Stock”), par value $0.01 per share, which is listed on the Nasdaq Capital Market under the symbol “AIMD,” at a price per share of 1.05 times the highest closing sale price of the Common Stock during the 30-trading day period preceding the effective date of the License Agreement. The License Agreement shall remain in effect until terminated by mutual written agreement of the parties, or until the expiration of the Licensed Patents, or all claims for alleged infringement of the Licensed Patents are barred by applicable laws.

     

    Following the issuance of the 5.5 million shares of stock, TCNT will control approximately 63.2% of the voting power of the Company. TCNT plans to enter into a voting agreement with Ainos KY and, pursuant to such voting agreement, will agree to vote all of the voting stock of the Company that is current owns or will acquire in the future in the manner determined by Ainos KY in its sole discretion.

     

    The foregoing description of the License Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the License Agreement, a copy of which is filed with this current report on Form 8-K as Exhibit 10.1 and is hereby incorporated herein by reference.

     

    Item 3.02 Unregistered Sales of Equity Securities

     

    As described in Item 1.01 above, the Company entered into the License Agreement on August 6, 2024, and agreed to issue 5,500,000 shares of Common Stock to TCNT in connection with the transaction contemplated by the License Agreement. The disclosure in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 3.02.

     

    Note Conversion

     

    As previously reported, on September 25, 2023, the Company entered into a securities purchase agreement with Lind Global Fund II LP (“Lind”) and issued a senior secured convertible promissory note, as amended on January 23, 2024 (the “Note”) to Lind. On August 5, 2024, the Company fully prepaid the remaining outstanding principal of the Note, totaling $1.67 million. The prepayment was made with $1,439,754 in cash and $224,842 through the issuance of 382,384 shares of Common Stock, valued at $0.588 per share.

     

    The issuances of the securities were made without registration under the Securities Act of 1933, as amended (the “Securities Act”), in reliance on the exemption provided by Section 4(a)(2) of the Securities Act as a transaction not involving a public offering.

     

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    As of August 9, 2024, Lawrence K. Lin transitioned from his role as the Company’s Executive Vice President of Operations, effective August 9, 2024. As a result of this transition, Mr. Lin no longer serves as an executive officer of the Company.

     

    Item 9.01 Financial Statement and Exhibits

     

    (d) Exhibits.

     

    Exhibit No.   Description
    10.1   Patent License Agreement, dated August 6, 2024, by and between Ainos, Inc. and Taiwan Carbon Nano Technology Corporation.
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

    2
     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      Ainos, Inc.
         
    Date: August 9, 2024 By: /s/ Chun-Hsien Tsai
      Name: Chun-Hsien Tsai
      Title: Chief Executive Officer

     

    3

    Get the next $AIMD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AIMD

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AIMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Ase Test, Inc. bought 29,476 shares (SEC Form 4)

    4 - Ainos, Inc. (0001014763) (Issuer)

    6/25/25 6:03:05 AM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIMD
    SEC Filings

    View All

    Ainos Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Ainos, Inc. (0001014763) (Filer)

    10/17/25 4:10:56 PM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Ainos Inc.

    DEF 14A - Ainos, Inc. (0001014763) (Filer)

    10/1/25 4:26:19 PM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ainos Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Ainos, Inc. (0001014763) (Filer)

    9/8/25 9:00:25 AM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Water Tower Research Spotlights Ainos' AI Nose Programs and Strategic Milestones for 2025

    Report highlights greater visibility in AI Nose developments, including robotics, smart manufacturing, elderly care monitoring, and women's health testing SAN DIEGO, CA / ACCESS Newswire / January 21, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a pioneer of digiting scent and low-dose interferon therapeutics, today announced that Water Tower Research ("WTR") has published a report projecting increased visibility for the Company's transformative AI Nose programs. The report emphasizes anticipated progress for AI Nose across multiple sectors, including robotics, smart manufacturing, elderly care, and women's health.Key Highlights from the Report:AI Nose Technolog

    1/21/25 10:00:00 AM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ainos Granted 180-Day Extension by Nasdaq to Regain Compliance With Minimum Bid Price Rule

    SAN DIEGO, CA / ACCESS Newswire / January 17, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), today announced that it had received written notification (the "Written Notification") from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") that the Company is eligible for a 180-day extension to regain compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Rule").As previously reported, on July 15, 2024, the Company received a deficiency letter from the Nasdaq notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company's common stock has been below

    1/17/25 9:00:00 AM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ainos Unveils AI Nose for Robotics: Invites Global Robotics Companies to Join Forces in Shaping the Future of Smell-Enabled Robots

    Ainos invites robotics and humanoid companies to join Ainos Alliance and digitize smell SAN DIEGO, CA / ACCESSWIRE / January 13, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW), a pioneer of digitizing scent, proudly announces its revolutionary AI Nose for robotics application and invites robotics companies worldwide to join Ainos Alliance. This technology aims to equip robots with the ability to "smell," filling a long-standing gap in sensory capabilities. Powered by advanced artificial intelligence (AI) and micro-electromechanical systems (MEMS) gas sensors, AI Nose redefines how robots interact with the world, enabling transformative applications across industrial, healthcare, and everyday

    1/13/25 10:00:00 AM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Taiwan Carbon Nano Technology Corp sold $25,130 worth of shares (7,000 units at $3.59), decreasing direct ownership by 0.67% to 1,037,206 units (SEC Form 4)

    4 - Ainos, Inc. (0001014763) (Issuer)

    10/8/25 4:10:18 PM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Taiwan Carbon Nano Technology Corp sold $7,170 worth of shares (2,000 units at $3.58), decreasing direct ownership by 0.19% to 1,044,206 units (SEC Form 4)

    4 - Ainos, Inc. (0001014763) (Issuer)

    10/6/25 5:54:13 PM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Taiwan Carbon Nano Technology Corp sold $9,425 worth of shares (2,706 units at $3.48), decreasing direct ownership by 0.26% to 1,046,206 units (SEC Form 4)

    4 - Ainos, Inc. (0001014763) (Issuer)

    10/2/25 4:10:39 PM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIMD
    Leadership Updates

    Live Leadership Updates

    View All

    Ainos Unveils AI Nose for Robotics: Invites Global Robotics Companies to Join Forces in Shaping the Future of Smell-Enabled Robots

    Ainos invites robotics and humanoid companies to join Ainos Alliance and digitize smell SAN DIEGO, CA / ACCESSWIRE / January 13, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW), a pioneer of digitizing scent, proudly announces its revolutionary AI Nose for robotics application and invites robotics companies worldwide to join Ainos Alliance. This technology aims to equip robots with the ability to "smell," filling a long-standing gap in sensory capabilities. Powered by advanced artificial intelligence (AI) and micro-electromechanical systems (MEMS) gas sensors, AI Nose redefines how robots interact with the world, enabling transformative applications across industrial, healthcare, and everyday

    1/13/25 10:00:00 AM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIMD
    Financials

    Live finance-specific insights

    View All

    Ainos Reports Third Quarter 2024 Financial Results

    Secured multi-regional patent assets, strengthening Ainos' AI Nose technology.Expanded VELDONA® patent portfolio with a new invention patent for treatments and preventions for coronavirus infections.Progressed clinical trials for VELDONA®, including new studies on Sjögren's syndrome and HIV-related oral warts. SAN DIEGO, CA / ACCESSWIRE / November 6, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today announced its financial results for the third quarter ended September 30, 2024.Chun-Hsien (Eddy) Tsai, Chairman of the Board, Preside

    11/6/24 4:30:00 PM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ainos Reports Second Quarter 2024 Financial Results

    Enrolling first subject for FCGS clinical study marks a solid start in shifting animal health emphasis to drug developmentsRobust financial runway for over 12 months following the prepayment of a senior secured convertible noteSAN DIEGO, CA / ACCESSWIRE / August 5, 2024 / Ainos, Inc. (NASDAQ:AIMD, AIMDW))) ("Ainos", or the "Company"), a diversified healthcare company focused on novel AI-powered point-of-care testing ("POCT") and low-dose interferon therapeutics ("VELDONA®"), today announced its financial results for the second quarter ended June 30, 2024.Chun-Hsien (Eddy) Tsai, Chairman of the Board, President, and Chief Executive Officer of Ainos, commented, "We've made meaningful progress

    8/5/24 4:15:00 PM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ainos Reports First Quarter 2024 Financial Results

    Strategic focus on VELDONA and AI-powered point-of-care testing continues during 2024US$9M growth capital secured in May strengthens financial position for executing growth strategy SAN DIEGO, CA / ACCESSWIRE / May 13, 2024 / Ainos, Inc. (NASDAQ:AIMD, AIMDW))) ("Ainos", or the "Company"), a diversified healthcare company focused on the development of novel point-of-care testing ("POCT"), low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced its financial results for the first quarter ended March 31, 2024.Chun-Hsien (Eddy) Tsai, Chairman of the Board, President, and Chief Executive Officer of Ainos, commented, "In the first quarter, we successfully

    5/13/24 4:10:00 PM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Ainos Inc.

    SC 13D/A - Ainos, Inc. (0001014763) (Subject)

    11/27/24 6:08:44 AM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Ainos Inc.

    SC 13D - Ainos, Inc. (0001014763) (Subject)

    8/21/24 8:22:28 PM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Ainos Inc.

    SC 13D/A - Ainos, Inc. (0001014763) (Subject)

    8/20/24 4:05:21 PM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care